Skip to content
zameds

Nasonex

Mometasone furoate

Loading the molecular structure
C27H30Cl2O6521.40 g/mol

[(8S,9R,10S,11S,13S,14S,16R,17R)-9-Chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate

Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 441336.

Registration

Applicants
1
Registrations
1

Applicants and registrations

ApplicantBrandsDosagesRegistrationsScheduleLeaflets
Organon South Africa (Pty) LtdNasonex100 mg320157Not determinedPIPIL

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Nasonex

EACH METERED-DOSE CONTAINS MOMETASONE FUROATE 50,0 ug

100 mgAqueous nasal spray32015732/21.5.1/0157Approved 19 January 2018RegisteredNot determinedPIPIL

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S4: Mometasone furoate

    • except when intended for inhalation or nasal administration.

    Consolidated Schedules 06 July 2026, line 7167

  • S3: Mometasone furoate

    • when intended for inhalation or nasal administration, except when intended for nasal administration as an aqueous spray, other than by pressurized aerosol, and indicated for the treatment of the symptoms of seasonal or perennial allergic rhinitis (hay fever) in adults and children between the age of 2 and 11 years of age, subject to
    • a maximum dose of 200 micrograms per nostril in adults and 50 micrograms per nostril in children; and
    • a maximum pack size of 200 doses. (S2, S4)

    Consolidated Schedules 06 July 2026, lines 3960 to 3965

  • S2: Mometasone furoate

    • when intended for nasal administration as an aqueous spray, other than by pressurized aerosol, and indicated for the treatment of the symptoms of seasonal or perennial allergic rhinitis (hay fever) in adults and children between the age of 2 and 11 years of age, subject to
    • a maximum dose of 200 micrograms per nostril in adults and 50 micrograms per nostril in children; and
    • a maximum pack size of 200 doses. (S3, S4)

    Consolidated Schedules 06 July 2026, lines 2284 to 2290

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Background

Loading...
Loading Wikipedia summary

SAHPRA documents

Professional information (PI)For healthcare professionalsNasonex, Organon South Africa (Pty) LtdPatient information leaflet (PIL)For patients and carersNasonex, Organon South Africa (Pty) Ltd

These documents come from SAHPRA's PI-PIL repository unless the line under a document says otherwise. Always consult with a healthcare professional for medical advice.

Research articles

Loading...
Loading PubMed articles